

**Pre-proposal Conference:
Meeting Minutes for UF BPA/VARR
February 17, 2016**

**Covering
DoD P&T Committee May 2016 Review and RFQ HT9402-16-Q-0002**

1. Attendance

Industry Liaison, DHA Pharmacy Operations Division

Contracting Officer-DHA Contract Management

Jr. Contract Analyst – DHA Contract Management

2. New Solicitation Website: <http://www.health.mil/About-MHS/Other-MHS-Organizations/DoD-Pharmacy-and-Therapeutics-Committee/Drug-Classes-New-Drugs-Under-Review/May-2016>

To access the new POD website, go to www.health.mil/POD

Drug Classes:

- a. **Oral Contraceptives-Emergency Contraceptives**
- b. **Anticonvulsants**
- c. **Antipsychotic Agents-Atypical**
- d. **Designated Newly Approved Drugs**
 - i. **Entresto**
 - ii. **Viberzi**
 - iii. **Zecuity**

3. Questions during Teleconference:

Q. Is Entresto going to be stepped to one product or many products? For example, is Entresto stepped to product X AND products A, B, C, D or is Entresto stepped to product X OR product A, B, C?

Answer: Step therapy exists for the RAAs class. See the August 2011 DoD P&T Committee Minutes for an example of the existing step therapy in the class. <http://www.health.mil/About-MHS/Other-MHS-Organizations/DoD-Pharmacy-and-Therapeutics-Committee/Meeting-Minutes>

Q. Is Entresto going to be stepped to agents in other Formulary classes outside of RENIN-ANGIOTENSIN ANTIHYPERTENSIVES?

Answer: Only a “within RAAs” class step would be considered.

Q. Prior Authorization (PA) clear description of this is needed. Some items we would like to know are:

- a. What is the exact criteria for the PA? Will it match what is on Entresto’s product insert or include criteria outside of the insert?

Answer: This will be presented at the May 2106 P&T Committee Meeting and is subject to recommendation from the P&T Committee members.

b. Has the PA been defined already or will it be defined at the day of the bid?

Answer: See above answer.

Q. What type of contracting vehicle will DoD use?

Answer: The UF BPA/ UF VARR Solicitation found here: <http://health.mil/About-MHS/Other-MHS-Organizations/DoD-Pharmacy-and-Therapeutics-Committee/Drug-Classes-New-Drugs-Under-Review/May-2016>

Q. Can we get a copy of the contracting vehicle to view before we bid?

Answer: The UF BPA/ UF VARR documents are on the above mentioned website.

Q. If we decide not to bid, what happens?

Answer: The P & T committee will evaluate at current pricing.

Q. Can we ask as a condition for a bid that we are placed at parity with a competitor?

Answer: No, All quotes will be reviewed as submitted and no conditions will be accepted.

Q. If a drug still does not have permanent pricing on the FSS contract (still at the temporary stage) at the time the bid is due, it is assumed the manufacturer CANNOT submit a BPA bid for the MTF and TMOP segments. It is assumed the manufacturer CAN instead submit a TPR or DAPA for those segments and this will have the same functionality as a BPA bid submission in terms of formulary positioning. Are both of these assumptions correct?

Answer: Part 1 = True. Reference Paragraph 10 of UF BPA solicitation.

Part 2 = False. TPRs and DAPAs do not have the same function as a BPA quote and will not be evaluated as such. See price evaluation on bottom of page 3 and top of page 4 of the solicitation. The reason is that both TPRs and DAPAs are temporary and do not form a reliable basis for a formulary decision, whereas the UF BPA provides guaranteed pricing for a minimum of one year.

Q. Since both a TPR and DAPA are discounts to be provided to the DoD is it acceptable to submit one or the other?

Answer: Yes, the TPR is submitted to the VA NAC, the DAPA is submitted to DLA DAPA Management Team.

For additional information on establishing a DAPA, contact Defense Logistics Agency (DLA) at PharmDAPA@dla.mil. See prior answer.

Q. What would the timing be to submit these TPRs or DAPAs? Any specific deadlines?

Answer: There are no specific deadlines; however, the DAPA does take about one month to put into place. Additional information can be found here: <http://health.mil/About-MHS/Other-MHS-Organizations/DoD-Pharmacy-and-Therapeutics-Committee> See "Formulary Management of FDA Innovator Drugs". See prior answer.

Q. In terms of the VARR for TriCare retail it is assumed the bid can be submitted normally using the templates on the website? Is this correct?

Answer: Yes, the UF VARR is on the website: <http://health.mil/About-MHS/Other-MHS-Organizations/DoD-Pharmacy-and-Therapeutics-Committee/Drug-Classes-New-Drugs-Under-Review/May-2016>

Q. Will you accept a DAPA for Vraylar?

Answer: No, need a price guarantee associated with the UF BPA and UF VARR.

Q. When was the last time the Atypical Antipsychotic class was last reviewed?

Answer: This UF Class has not been previously reviewed by the DoD P&T Committee.

4. Topics Discussed

- a. The vendor name in paragraph 1, 10(b), 12 and the FSS contract number must match, cannot accept (example given) ABC Contractor on the Quote and the FSS Master Agreement has ABC Supplier.
- b. The FSS contract number in paragraph 10 (b) and the FSS contract itself must match.
- c. The unit price per dosage must be the same.

Example given; 500 mg, 30 tablet bottle, 500 mg 60 tablet bottle, 500 mg 90 table bottle must all have the same price of \$0.34 (the two decimal pricing).

- d. If there is a discrepancy between the unit price and the NDC price, the NDC price will take precedence; however, the unit price per dose should match.
 - e. Must submit a pricing appendix for each NDC within the class unless an exception is submitted. The exception needs to be submitted and approved by the contracting officer prior to the cut off time and due date of the quote submittal.
 - f. If there are clerical errors on the quote submission and the quote is submitted early we may have time to fix the error, but it will be on a case by case basis. It is advised to submit quotes early if possible.
 - g. The government is not soliciting UF BPA or UF VARR quotes for innovator drugs. Innovator drugs scheduled for review will be posted to the website on or about 13 April 2016.
 - h. Unless a request to exclude specific institutional or hospital unit dose packaged NDCs are submitted in advance and approved by the DHA Contracting Officer in writing, no exclusions will be approved and this in accordance with paragraph 8 of the UF BPA. Exclusions do not apply to the UF VARR, only to the UF BPA. All NDCs, institutional or otherwise, will be billed accordingly according to the terms in the UF VARR.
5. Briefed some of the important differences in the solicitation documents from the past, and advised that all read the documents carefully. Some key differences:
- a. Pricing submission requirements have been changed to two decimal places for both the price per unit of measure and NDC, and the NDC pricing will take precedence.
 - b. Combined instructions, BPA and VARR into a single file.